[Current status of neuroleptic long term treatment of schizophrenia].
D000553:Ambulatory Care; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D002908:Chronic Disease; D003692:Delayed-Action Preparations; D005475:Flupenthixol / Q000009:adverse effects / Q000627:therapeutic use; D005476:Fluphenazine / Q000009:adverse effects / Q000627:therapeutic use; D005484:Fluspirilene / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008134:Long-Term Care; D010395:Penfluridol / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D011379:Prognosis; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy* / Q000534:rehabilitation; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D003692:Delayed-Action Preparations; D010919:Placebos; D014149:Tranquilizing Agents; D010395:Penfluridol; D005484:Fluspirilene; D005475:Flupenthixol; D005476:Fluphenazine
Gegenwärtiger Stand der neuroleptischen Langzeitbehandlung der Schizophrenie